Cytotoxic T-Lymphocytes for the Prophylaxis of Cytomegalovirus After Allogeneic Stem Cell Transplant (VICTA)

This study has been completed.

Sponsor:

Collaborators:

Center for Cell and Gene Therapy, Baylor College of Medicine

The Methodist Hospital System

Texas Children's Hospital

National Heart, Lung, and Blood Institute (NHLBI)

Information provided by (Responsible Party):

Helen Heslop, Baylor College of Medicine

ClinicalTrials.gov Identifier:

NCT00078533

First received: March 1, 2004

Last updated: October 6, 2014

Last verified: June 2014

History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been completed.
Study Completion Date:	June 2011
Primary Completion Date:	July 2010 (Final data collection date for primary outcome measure)

No publications provided by Baylor College of Medicine

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Hanley PJ, Cruz CR, Savoldo B, Leen AM, Stanojevic M, Khalil M, Decker W, Molldrem JJ, Liu H, Gee AP, Rooney CM, Heslop HE, Dotti G, Brenner MK, Shpall EJ, Bollard CM. Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes. Blood. 2009 Aug 27;114(9):1958-67. doi: 10.1182/blood-2009-03-213256. Epub 2009 May 14.

To Top